Clinical Trial 20159

Cancer Type: Breast
Study Type: Treatment
NCT#: NCT03821233

Phase: Phase I
Principal Investigator: Han, Heather

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 1 Study of ZW49 in Patients with Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers

Summary

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum- tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.

Objective

primary: To determine the maximum tolerated dose (MTD)/recommended dose (RD) of ZW49; To characterize the safety and tolerability of ZW49. secondary: To evaluate the pharmacokinetics (PK) of ZW49; To evaluate the immunogenicity of ZW49; To evaluate the anti-tumor activity of ZW49 in human epidermal growth factor receptor 2 (HER2)-expressing cancers.

Treatments

Therapies

Therapy (NOS)

Medications

ZW49 ()

Inclusion Criteria

Pathologically-confirmed diagnosis of breast cancer, gastroesophageal adenocarcinoma (GEA), or other HER2-expressing cancer with evidence of locally advanced (unresectable) and/or metastatic disease. During dose expansion, all subjects must have HER2-high disease, including IHC 3+, or IHC 2+ and FISH +. Dose-escalation (Cohort 1): HER2-high advanced solid tumors. Expansion (Cohort 2): HER2-high breast cancer. Expansion (Cohort 3): HER2-high GEA. Expansion (Cohort 4): HER2-high other non-breast and non-GEA cancers

Progressive disease that has progressed on or been refractory to all standard of care. Patients who were intolerant to or ineligible for standard therapy may be eligible if the reasons are carefully documented and approval is provided by the sponsor medical monitor. Patients with HER2-high breast cancer must have received prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Patients with HER2-high GEA must have received prior treatment with trastuzumab

Sites of disease assessible per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Dose-escalation: measurable or non-measurable disease. Expansion: measurable disease

ECOG performance status score of 0 or 1

Adequate organ function

Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal

Exclusion Criteria

Prior treatment with ZW25, the investigational HER2-targeted monoclonal antibody

History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure (CHF)

Clinically significant infiltrative pulmonary disease not related to lung metastases

Active hepatitis B or hepatitis C infection or other known chronic liver disease

Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gall stones, liver metastases, or stable chronic liver disease per investigator assessment)

Known history of human immunodeficiency virus (HIV) infection

Brain metastases: Untreated CNS metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as patients who are off steroids and anticonvulsants and are stable for at least 1 month at the time of screening).

Known leptomeningeal disease (LMD)

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trials Search

Advanced Search